1月6日 - ** 药物开发商Apogee Therapeutics APGE.O股价盘前上涨1.66%至78.35美元
** 该公司称，其实验性药物zumilokibart在一项针对轻度至中度哮喘成人患者的早期试验中显示出强劲的疗效
** Zumilokibart 可减少成人气道炎症 - AGPE
** 公司称，单次用药后，疗效可持续32周；未发现严重副作用。
** 公司的 Zumilokibart 还在接受特应性皮炎（一种慢性皮肤病）的测试 - AGPE
** Apogee 预计今年将获得更多试验数据，并计划明年开始后期研究
** 截至上次收盘，股价在过去一年中上涨了 ~3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.